Pulmonary Arterial Hypertension Market Progresses for Huge Profits by the End 2020

0
40

The global pulmonary arterial hypertension (PAH) market is progressing at a high CAGR of 17.90% within a forecast period of 2014 to 2020. This market was recorded at US$4.04 bn in 2013, and is expected to reach US$5.19 bn by the end of 2020. The data is presented in a unique and comprehensive manner in a research report released by Transparency Market Research, titled “Pulmonary Arterial Hypertension (PAH) Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020.”

Pulmonary arterial hypertension is when the blood pressure inside the small arteries within the lungs increases. PAH can cause swelling of legs, fainting, dizziness, and shortness of breath, among other more serious symptoms. One of the biggest problems that a patient with PAH suffers is an extremely low tolerance to exercise. PAH can escalate into pulmonary vascular resistance and cause the failure of the right ventricle.

According to the report, the primary driver for the global PAH market is the list of newly-approved drugs and medical products aimed at treating PAH. A large number of medical products are already approved, while more are still in the pipeline. Another factor promoting the growth of the global PAH market is the increasing number of leaps taken in research and development efforts, aided by government policies and other initiatives.

The report provides a segmented analysis of the global PAH market. These segments are sorted within the categories of drug class and geography. The report also provides an extensive analysis of the pipeline drugs in the global PAH market.

Request to View Sample of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181

In terms of drug class, the global PAH market is segmented into soluble guanylate cyclase (sGC) stimulators, phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor antagonists (ERAs), and prostacyclin and prostacyclin analogs. Of these, the report’s authors have put the prostacyclin and prostacyclin analogs segment ahead of the ERA segment, which means that the segment will lead the global PAH market by 2023, surpassing the current leader, ERAs.

The report’s geographical segmentation of the global PAH market reveals Asia Pacific to be the fastest-growing region for the given forecast period. The growth rate of this region is attributed to major opportunities that will be found in Australia, New Zealand, Japan, China, and India. Enterprises operating in these regions could take advantage of these opportunities and increase their profits and presence in the market.

Leave a Reply